Knowledge-seeker and psychologist Stuart Kelter shares his joy of learning and “delving in.” Ready? Let’s delve... Join Chris Churchill on the possible reasons why the search for intelligent life in the universe is coming up empty. Let’s hear from Israeli psychiatrist Pesach Lichtenberg about a promising approach to schizophrenia—going mainstream in Israel—that uses minimal drugs and maximal support through the crisis, rejecting the presumption of life-long disability. Find out what Pulitzer Prize winning historian, David Kertzer learned from recently opened Vatican records about Pius XII, the Pope During WWII. We explore the fascinating and intriguing... What did journalist Eve Fairbanks learn about race relations in post-Apartheid South Africa? Did you realize there were dozens and dozens of early women scientists? Let’s find out about them through a sampling of poems with poet Jessy Randall. How shall we grapple with the complexities of the placebo effect in drug development and medical practice? Harvard researcher Kathryn Hall confirms just how complicated it really is! But beware: increasing one’s knowledge leads to more and more questions...
https://delving-in.captivate.fm
episode 20: #20. The Awesome Benefits and Potential Dangers of Recent Advances in Gene-Editing Technology
Fyodor Urnov is a Professor of Molecular Therapeutics at UC Berkeley and a Scientific Director at its Innovative Genomics Institute. He co-developed the toolbox of human genome and epigenome editing and led the team that developed a strategy for genome editing in the hemoglobinopathies, sickle cell disease and beta-thalassemia, that has yielded sustained clinical benefit for subjects in several ongoing clinical trials. At the IGI Fyodor directs efforts to develop scalable CRISPR-based approaches to treat diseases of the immune system, sickle cell disease, neurodegeneration, and neuroinflammation. His recent op-ed in the New York Times describes a major goal for the field of genome editing, and a key focus of Fyodor's work at the IGI - expanding access to CRISPR therapies for N=1 genetic disease.
(Recorded 3/2/23.)